Unten finden Sie die vollständige Liste unserer Pressemitteilungen (Seite 11 von 28):
Jeune Aesthetics taps BOTOX® leader Marc Forth as CEO to drive growth in skin rejuvenation therapies.
ImmuCell taps IDEXX veteran Timothy Fiori as CFO to strengthen financial strategy and fuel future growth.
The KAFTRIO label expands in the EU to treat younger patients with non-class I mutations, allowing broader access in key countries.
AbbVie's RINVOQ becomes first oral therapy approved in EU for giant cell arteritis, offering new hope to patients.
EC approves subcutaneous RYBREVANT® + LAZCLUZE® for NSCLC with EGFR mutations using Halozyme's ENHANZE® drug delivery technology.
Rhythm’s Phase 3 trial shows major BMI reduction in rare hypothalamic obesity, FDA filing set for Q3 2025.
Troculeucel shows improved cognition and biomarker shifts in small Alzheimer’s study—Phase 2a now underway.
MaaT033 safely passes Phase 2b checkpoint in stem cell transplant patients, trial advances across Europe.
Veranova appoints Dr. Zugel as Global VP of Analytical Ops, boosting R&D with deep industry and GMP lab experience.
Health Canada grants Priority Review to AGAMREE, a potential first DMD treatment in Canada by end of 2025.
J&J’s nipocalimab shows durable gMG benefits, improving symptoms and reducing steroid use in Phase 3/OLE data.
Indivumed unveils novel cancer targets, expands leadership, and accelerates CRC drug discovery with AI and biobank.
Valneva and LimmaTech launch Phase 2 infant trial for S4V2, a vaccine to prevent life-threatening shigellosis.
Artiva appoints Dr. Banerjee as CMO to accelerate AlloNK’s development for autoimmune diseases.
ValoTx appoints Marcella Origgi as CEO to lead PeptiCRAd-1 trials and global immuno-oncology efforts.
The FDA accepted Outlook's ONS-5010 BLA with the Aug 27, 2025, PDUFA goal based on the clinical trial data.
Tolebrutinib delays MS disability in nrSPMS patients, NEJM publishes results; FDA review set for Sep 28, 2025
Cytosurge appoints Simon Egli as CEO; co-founder Pascal Behr to guide strategy as Board Delegate in 2025.
TRYVIO label updated by FDA, removing REMS and enabling broader use for resistant hypertension patients in retail.
Corvus welcomes biotech leader Richard van den Broek to its board, supporting ITK inhibitor clinical strategy.
Tonix and Makana team up to combine TNX-1500 with GE pig organs for xenotransplantation therapy development.
Grace Therapeutics receives FDA guidance supporting NDA submission for GTx-104 IV nimodipine in aSAH treatment.
Tevogen Generics launches to lower drug costs and expand U.S. pharma manufacturing; Sadiq Khan named interim lead.
IDEAYA launches Phase 1/2 expansion of IDE397–Trodelvy combo trial for MTAP-deletion urothelial cancer patients.
Pharma Live 2025 hits Mumbai April 17–19 with 35K+ attendees, 200+ exhibitors & keynotes on AI, diagnostics, APIs.
Pharma Now joined INTERPHEX 2025 in NYC, featuring Learning Labs, tech demos, and key pharma partnerships.
Arcutis CFO David Topper to retire in May; Latha Vairavan steps in to lead financial operations amid company growth.
Circio signs agreement with Lonza to evaluate circular mRNA technology in Lonza's expression system for protein production.
Jennifer Cote steps down as CFO of Harvard Bioscience; Mark Frost named interim replacement with effect in May.
CRL launches Single-Use Gamma Bags, engineered for gamma sterilization to meet pharma and biotech standards.
Icotrokinra shows significant skin clearance and safety in adolescents with plaque psoriasis in Phase 3 trial data.
Baxter introduces Hemopatch with room temperature storage, enhancing access for bleeding control in surgeries across Europe.
Shuttle Pharma advances PSMA-targeted cancer therapy with a new patent for PARP conjugates in metastatic prostate cancer.
Phase 1/2a trial of [212Pb]VMT01 starts monotherapy cohort for metastatic melanoma, including brain metastases.
Sun Pharma appoints Shaik Barak Tulla as SVP to drive commercial excellence and global business growth.
Eyestem reports promising vision improvement and safety in Phase 1 trial for dry AMD cell therapy Eyecyte-RPE™.
Roche's Columvi + GemOx was approved in the EU for relapsed/refractory DLBCL, doubling survival compared to standard therapy.
IDEAYA wins FDA backing to start Phase 3 trial of darovasertib in primary uveal melanoma patients.
Celularity supports CMS move delaying LCD on wound care, preserving Medicare access and enabling reform talks.
Cue and Boehringer collaborate on targeted T-cell therapy to transform autoimmune disease treatment.
Sanofi’s amlitelimab shows efficacy in inflammatory asthma; the pipeline expands with multiple Phase 2/3 studies in respiratory disease.
Lifecore welcomes Tom Salus as Chief Legal Officer, bringing 30+ years of legal and life sciences expertise.
MetaVia's DA-1726 achieves 6.3% weight loss with good tolerability in Phase 1 trial; shows promise for obesity and T2D.
Wiley teams up with Anatek to provide advanced spectral databases and tools to analytical labs across India.
Charlotte Moser joins Parexel as CMO, bringing 25+ years of leadership in clinical development and oncology research.
Vivani and Okava broaden OKV-119 development for ageing dogs, aiming to tackle obesity and diabetes and extend lifespans.
Telix’s TLX101 extends survival in recurrent glioma; early Phase 2 data confirms safety and efficacy at NMN Symposium.
Nobel Prize winner Dan Shechtman joins NeuroNOS’s SAB to support breakthrough ASD and Alzheimer’s research.
Dr. Rebecca Taub becomes advisor; Dr. David Soergel named CMO as Madrigal advances MASH treatment pipeline.
Industry leaders shared practical strategies and insights on aseptic processes at Pharma Now’s 2025 event in Ahmedabad.
Phathom adds Ted Schroeder to its Board to strengthen commercial strategy and expand VOQUEZNA®’s reach.
ACIP recommends Bavarian Nordic’s VIMKUNYA™ single-dose chikungunya vaccine for at-risk travellers and lab workers.
Scilex gains FDA orphan designation for colchicine in pericarditis, expanding beyond pain into rare inflammatory diseases.
Addex regains ADX71149 rights as Janssen exits the epilepsy program; the partnership officially ends with the return of asset rights.
Vabysmo improves vision and retinal swelling in angioid streaks. Patients meet Phase III endpoints with a good safety profile.
Dr. Robert Langer joins Decoy Therapeutics' SAB post-Salarius merger, enhancing innovation in peptide therapeutics.
Werewolf appoints Steven Bloom as CBO to drive growth as it advances breakthrough immunotherapy programs.
Design Therapeutics welcomes Dr. Storgard as CMO to advance clinical milestones for genetic disease treatments.
NewAmsterdam appoints pharma veteran Adele Gulfo to its board, enhancing leadership with decades of industry success.
Tevogen Bio collaborates with CD8 to develop a facility that enables in-house research and GMP cell therapy production.
BVI Medical's FDA-cleared Leos™ system revolutionises glaucoma care with advanced laser and imaging technology.
Africa CDC and WHO updated the mpox plan to boost control, vaccines, and resilience amid the global case surge.
Atea names Dr. Berman as Board observer under new deal with Radoff-JEC Group, who will support nominees at the 2025 vote
Lilly’s oral GLP-1 drug, orforglipron, shows strong results in type 2 diabetes and weight management trial.
Biotech leader Craig Wheeler joins Apellis Board to boost innovation and advance strategic vision in groundbreaking C3 therapies. Read More!
Enhertu plus pertuzumab demonstrates superior progression-free survival compared to THP in patients with HER2+ metastatic breast cancer. Read more!
Elutia initiates a multi-center study to assess the safety and performance of EluPro™ in patients undergoing CIED implantations and neurostimulation procedures.
Medicus expands SKNJCT-003 trial to 90 patients after IRB approval; interim data shows strong efficacy and safety for treating BCC.
Achieve’s cytisinicline Phase 3 results published in JAMA, showing strong efficacy and tolerability for smoking cessation; NDA planned for June 2025.
Jazz completes $935M Chimerix acquisition, gains promising brain cancer drug dordaviprone, under FDA Priority Review with a PDUFA date in August 2025.
A Myriad Genetics study published in the Journal of Clinical Psychopharmacology reveals that GeneSight testing led to a 39% reduction in psychiatric-related hospitalizations for depression patients.
NeuroNOS receives FDA Orphan Drug Designation for BA-102, a therapy targeting Phelan-McDermid Syndrome, a rare neurodevelopmental disorder linked to autism.
Roche to invest $50B in the U.S. over 5 years, creating 12,000+ jobs and expanding R&D, manufacturing, and diagnostics capabilities.
Sun Pharma & Ambuja Foundation start a 4-year water management project in Dhari, Gujarat, to improve irrigation, farming, and groundwater for 40 villages.
HUTCHMED completes Phase II enrollment for savolitinib in MET+ gastric cancer, aims for China approval in 2025.
Cassava announces Dr. Kupiec’s retirement and Dr. Moore’s appointment as Senior VP of Clinical Development, effective April 2025.
Rob Bancroft appointed CEO of AEON Biopharma, bringing 25+ years of life sciences leadership.
Rona Therapeutics gets NMPA approval for RN1871, an siRNA drug for hypertension, advancing to clinical trials in China.
BiomatiQ inaugurates world-class life science manufacturing facility in Hyderabad to advance life science manufacturing in India.
Abivax adds Dr. Dominik Höchli to Board, strengthening leadership ahead of Phase 3 ulcerative colitis data expected in Q3 2025.
Regeneron to nearly double biologics manufacturing through Fujifilm partnership, boosting U.S. capacity with a $3B+ investment and expanded job creation.
- Charles River reveals new cancer research platforms ahead of AACR 2025, including AI-driven analysis, humanised models, and 3D tumour screening tech.
1Cell.Ai launches OncoIncytes to power next-gen precision oncology with AI and single-cell insights.
- MetaVia’s DA-1726 demonstrates promising weight loss and safety in Phase 1 trial, with follow-up studies planned targeting Wegovy dropouts.
Tagworks starts Phase 1 trial of TGW101, a novel ADC; appoints Keith Orford as Chief Medical Officer.
Ascletis reports strong Phase Ib results for oral GLP-1R agonist ASC30 in obesity and submits 13-week Phase IIa study plan to FDA.
Gannet BioChem appoints Dr. Harry Rathore to its Board, bringing 35+ years of expertise to drive growth in specialty chemicals and CDMO services.
Roche's Chest Pain Triage algorithm earns CE mark, enhancing ACS detection and emergency care with AI-driven diagnostics via navify Algorithm Suite.
Voyager SPAC to merge with VERAXA Biotech, creating a Nasdaq-listed firm focused on next-gen cancer therapies.
DIOSynVax and ACM Biolabs team up on a universal bird flu vaccine, aiming for needle-free, global pandemic protection.
Clearmind launches CMND-100 clinical trial for Alcohol Use Disorder at Yale, Johns Hopkins, and IMCA, advancing psychedelic-based treatment research.
Coave Therapeutics appoints Romain Pettenaro to lead U.S. business development, enhancing its strategic focus on gene therapy innovation and growth.
Zealand Pharma begins Phase 2b ZUPREME-2 trial of petrelintide for overweight or obese adults with type 2 diabetes to assess efficacy and safety.
Zealand Pharma names Utpal Singh Chief Scientific Officer to lead peptide therapeutics discovery and drive innovation in obesity and metabolic diseases.
Pfizer to highlight 60+ studies at ASCO 2025, with new data on ADCs, BRAFTOVI®, XTANDI®, VERITAC-2, and epigenetic modulators.
Plus Therapeutics names Kyle Guse to its Board of Directors, bringing deep finance, legal, and biotech experience to support CNS radiotherapeutics strategy.
Cardiff Oncology secures U.S. patent for onvansertib-bevacizumab combo in mCRC; Phase 2 trial data expected in 1H 2025.
Artax Biopharma to present Phase 2a AX-158 psoriasis trial data in a prestigious late-breaking oral session at SID 2025, held in San Diego, CA.
Biomerica's Fortel® Ulcer Test for H. pylori detection gains approval from UAE Ministry of Health, offering rapid diagnosis for gastrointestinal diseases.
Mineralys publishes Phase 2 Advance-HTN results in NEJM, showing lorundrostat's strong efficacy in lowering blood pressure in resistant hypertension.
Calidi Biotherapeutics names Eric Poma, Ph.D., as CEO, marking a leadership transition to advance its virotherapy platform for cancer treatment.
Akoya and STCC partner on the SUPER study to identify spatial biomarkers that predict patient response to cancer immunotherapy in Singapore.
Inventiva identifies a biomarker that predicts responses to lanifibranor in MASH patients. Data was published in Clinical Gastroenterology and Hepatology.
Hikma sees strong growth across Injectables and Branded segments, reinforces U.S. manufacturing, and boosts R&D for long-term momentum.
Hikma sees strong growth across its Injectables and Branded segments, strengthens U.S. manufacturing, & accelerates R&D investments to drive long-term momentum.
AbbVie seeks FDA approval for TrenibotE, a novel short-acting neurotoxin with rapid onset designed for treating glabellar lines and attracting new users.
Actimed Therapeutics appoints Shaun Claydon as CFO to enhance leadership and advance innovation in treatments for muscle-wasting diseases. Read more!
Avidicure secures $50M in seed funding to advance its multifunctional antibody therapy for cancer, targeting innovative treatments with reduced toxicity.
DYNE-251 earns EMA orphan drug designation for Duchenne muscular dystrophy, strengthening Dyne's commitment to rare neuromuscular disease treatment.
FluidForm Bio publishes breakthrough CHIPS tissue platform in Science Advances, marking major progress in bioprinted, insulin-secreting therapies.
NurExone names Jacob Licht as CEO of Exo-Top and VP at NurExone, strengthening U.S. operations and completing its relocation from Alberta to Ontario.
DYNE-251 receives EMA orphan drug status for Duchenne muscular dystrophy, advancing Dyne’s efforts in rare neuromuscular diseases.
Beyond Air secures U.S. Patent for using gNO to treat NTM lung infections, offering a new treatment option for patients.
Merck KGaA, Darmstadt, Germany acquires SpringWorks Therapeutics for $3.9B to strengthen its rare tumor and U.S. healthcare market presence.
BEYONTTRA® (acoramidis) approved in the UK for ATTR-CM, offering near-complete TTR stabilization and improved patient outcomes, based on Phase 3 study success.
Portage Biotech reports strong PORT-7 preclinical results, prepares for human trials, and plans a PORT-6/PORT-7 combo to advance cancer immunotherapy.
Zentalis Pharmaceuticals begins dosing in DENALI Part 2 trial of azenosertib, targeting Cyclin E1+ PROC, aiming for accelerated approval if successful.
Explore Goldstab's comprehensive guide on Various BIS standards for UPVC Pipes to ensure compliance and reliable performance in your piping systems.
- Tevogen forecasts $1B first-year oncology sales and $10–14B over five years, highlighting its rapid, cost-effective drug development blueprint.
ADMA Biologics secures FDA approval for a new production process, boosting yields by 20%, enhancing efficiency, and advancing plasma-derived products.
Jade Biosciences finalizes Aerovate merger, secures $300M in funding, and advances JADE-001 for IgA nephropathy to transform autoimmune disease treatment.
PacBio licenses CUHK’s deep learning tech to expand methylation detection in HiFi sequencing, enabling 5hmC, hemimethylation, and 6mA profiling.
AAVantgarde names Rasmus Holm-Jorgensen as Chief Financial Officer to strengthen leadership, support strategic growth, and advance gene therapy programs.
AstraZeneca halts the CAPItello-280 Phase III trial of Truqap (capivasertib) in metastatic castration-resistant prostate cancer due to interim data failing to meet primary endpoints.
Krystal Biotech gets EC approval for VYJUVEK® to treat DEB, offering the first gene therapy for COL7A1 mutations in patients from birth across Europe.
Mesoblast appoints Lyn Cobley, former CEO of Westpac Institutional Bank, to its Board of Directors, bringing over 30 years of global financial expertise.
Roche's VENTANA TROP2 CDx, an AI-powered diagnostic device, earns FDA Breakthrough Designation for supporting NSCLC therapy & advancing lung cancer diagnostics.
Bayer announces Guru Ramamurthy as CFO of its Crop Science division, effective July 2025, bringing over 20 years of global finance leadership to the role.
Fablab names Mayur Hedaoo as Group CEO, advancing its global pharma & healthcare innovation with tech-driven, purpose-led leadership.
Adagene welcomes Dr. John Maraganore, former CEO of Alnylam Pharmaceuticals, as Executive Advisor to provide strategic guidance and support growth in antibody-based therapies.
Annovis Bio appoints Hui Liu as Director of Biostatistics, bringing 19+ years of clinical trial expertise across multiple therapeutic areas to leadership team.
CytoDyn will participate in the ESMO Breast Cancer 2025 Conference in Munich on May 15, highlighting advancements in breast cancer research and therapies.
Ardelyx names Merdad Parsey, M.D., Ph.D., to its Board of Directors, bringing biotech leadership and clinical expertise to advance the company’s mission.
INX-315 granted FDA Fast Track status for CCNE1-amplified platinum-resistant ovarian cancer, accelerating its path toward potential treatment approval.
Aclaris Therapeutics names Jesse Hall, M.D., as Chief Medical Officer to lead clinical strategy and innovation in immuno-inflammatory disease programs.
Therini Bio announces promising Phase 1a trial results for THN391, showing safety and tolerability in healthy volunteers for Alzheimer’s and retinal diseases.
Charles River’s new incubator welcomes 6 biotech innovators, offering mentorship and global resources to fast-track cell and gene therapies.
Abivax completes patient enrollment for its Phase 3 ABTECT trials of obefazimod, aiming to treat moderately to severely active ulcerative colitis.
Sandoz and Henlius sign a $301M global licensing deal to commercialize an ipilimumab biosimilar across the US, EU, and Japan, expanding their oncology reach.
Rinvoq (upadacitinib) gets FDA approval as the first oral JAK inhibitor for giant cell arteritis in adults, based on strong Phase III SELECT-GCA results.
AbbVie receives FDA approval for RINVOQ in GCA, supported by intense Phase 3 results showing higher sustained remission vs. placebo.
Merck begins $1B biologics facility in Delaware to produce KEYTRUDA and next-gen therapies, expected to create 500+ new jobs in the region. Read more!
Perspective Therapeutics begins Phase 1/2a trial, dosing first patient with [212Pb]PSV359 to evaluate safety and efficacy in FAP-α solid tumours.
Pharma Now launches its April–May 2025 magazine packed with expert insights, AI in pharma, regulatory updates, leadership stories & market trends.
Explore highlights from the Pharma Quality Excellence Awards 2025 in Mumbai, recognising top pharma innovators and quality champions.
Nipro India starts producing high-quality glass cartridges for dental and pen applications to meet increasing market demand.
Cassava appoints Dr. Bordey as SVP, Neuroscience to lead preclinical research on simufilam for TSC-related epilepsy and expand pipeline programs.
Mark F. Kubik joins Akari Therapeutics to lead business development for their ADC platform and AKTX-101 in oncology.
BioCardia enrolls first patient in Phase 3 CardiAMP HF II trial to evaluate autologous cell therapy for heart failure, advancing treatment options.
Dr. Olivier Brandicourt, former Sanofi CEO, joins Vaxcyte’s Board to support vaccine innovation and global commercialization strategy.
Windtree secures Houston property deal to generate rental income while advancing its cardiovascular and oncology drug pipeline.
Shinya Tsuzuki, formerly a top analyst at Mizuho Securities, joins Nxera Pharma as Head of Investor Relations, reporting to the CFO.
Foghorn Therapeutics appoints Dr. Neil Gallagher and Stuart Duty to its board, strengthening clinical and strategic leadership.
Adial Pharmaceuticals receives U.S. patent for using AD04 in genetically defined patients with alcohol or opioid-related disorders.
Elutia regains U.S. sales rights to its cardiovascular products, boosting margins and appoints Dwayne Montgomery to lead the new division.
BOTOX® Cosmetic expands its Confidence Project to support 250 women with training, mentorship, and $20K grants.
Breztri Aerosphere showed meaningful lung function improvements in Phase III asthma trials, with no new safety concerns.
MHRA approves VIMKUNYA for ages 12+, expanding chikungunya protection as Bavarian Nordic readies UK launch ahead of 2025 travel season.
ARS Pharma and ALK-Abelló team up to bring neffy® nasal epinephrine to more U.S. pediatricians, improving access for kids with severe allergies.
REC-4881 demonstrates up to 82% polyp burden reduction in FAP Phase 1b/2 trial, with a favorable safety profile and potential first-in-class promise.
Context Therapeutics appoints Dr. Karen Smith as interim CMO to lead clinical strategy and ensure continuity during a key leadership transition.
Autonomix concludes its first trial phase, showing significant pain relief, opioid reduction, and no serious adverse events in clinical trial participants.
Scorpius Holdings announces a $6M cost-saving plan, explores halal-certified CDMO facilities in Malaysia, and appoints key board members for global expansion.
Teva and Alvotech's SELARSDI gains FDA approval as an interchangeable biosimilar to Stelara, expanding treatment options for immune-mediated diseases.
PacBio and Chulalongkorn University launch Asia-Pacific's first newborn genome screening using HiFi WGS to detect rare conditions early in Thailand.
Moleculin secures two new U.S. patents for Annamycin, strengthening IP for its cancer therapy with no known cardiotoxicity or dose-limiting toxicity.
Immutep’s efti + KEYTRUDA® shows 17.6 months OS in head and neck cancer patients with CPS <1, outperforming standard treatments in clinical results.
Alterity's ATH434 receives FDA Fast Track designation for treating Multiple System Atrophy, accelerating its development and review process.
RetinalGenix leases lab space at MBC BioLabs to develop its DNA/RNA/GPS platform and repurpose drugs for neurodegenerative and ophthalmic diseases.
BioNTech names Ramón Zapata-Gomez as CFO, starting July 2025, to lead financial strategy and support upcoming oncology product launches and global growth.
Capricor clears FDA mid-cycle review for deramiocel in DMD-cardiomyopathy; no issues found. PDUFA approval decision expected by August 31, 2025.
Phase 1/2 trial data of IMNN-001 plus chemo for ovarian cancer to be published in *Gynecologic Oncology* and presented at ASCO 2025, highlighting key findings.
EU greenlights Calquence plus bendamustine/rituximab for untreated MCL in transplant-ineligible adults, based on ECHO trial showing 27% risk reduction.
INBS debuts Localised websites in Arabic, Italian, and Spanish to boost sales of its drug screening tech in Latin America, the Middle East, and Southern Europe.
Roche debuts Elecsys PRO-C3 test for fast, accurate liver fibrosis staging in MASLD patients, enabling earlier intervention and guiding new treatment options.
Mersana Therapeutics restructures, cutting workforce by 55% to prioritize breast cancer ADC programs and extend cash runway through mid-2026.
Galimedix completes SAD phase of GAL-101 Phase 1 trial, showing promising safety & pharmacokinetics for amyloid beta aggregation in neurodegenerative diseases.
Opus Genetics’ gene therapy for LCA5 receives FDA RMAT designation, expediting development for inherited retinal disease and advancing treatment options.
Essential Pharma appoints Duncan Ferguson as VP, Commercial, to lead strategy and growth in rare disease treatments with 25+ years of experience.
ENA Respiratory strengthens INNA-051's development with Kenny Simmen, PhD, and Alison Humbles, PhD, as strategic advisors for viral infection treatments.
Syndax’s Phase 2 data on revumenib for mNPM1 AML published in Blood, supports sNDA submission under FDA’s RTOR program for expanded label approval.
Theriva’s VCN-01 improves survival outcomes in Phase 2b VIRAGE trial for first-line metastatic PDAC, with manageable side effects and dose-dependent benefits.
Hepion pivots into diagnostics with CE-marked tests for celiac, HCC, H. pylori, and respiratory diseases, targeting $ 15 B+ market with strong growth potential.
Alvotech expects minimal financial impact from U.S. tariffs on imported pharmaceuticals, as costs fall to customers and not the company.
GRI Bio completes Phase 2a patient enrollment for GRI-0621 in IPF; interim analysis on track for Q2 2025, with topline results expected by Q3 2025.
Orchestra BioMed adds 27 patents to its AVIM therapy IP, advancing hypertension and heart failure treatments with FDA Breakthrough Designation.
EMA reviews Valneva’s chikungunya vaccine IXCHIQ® after reports of serious adverse events in adults 65+. Use remains unchanged for ages 12 to 64.
Trogenix adds Prof. Nada Jabado and Prof. Burkhard Becher to its Scientific Advisory Board, enhancing focus on pediatric oncology and immunotherapy.
DESTINY-Breast11 Phase III trial shows Enhertu plus THP improves pathologic complete response in high-risk HER2-positive early-stage breast cancer.
ARS Pharma launches neffy, a needle-free epinephrine nasal spray for kids with severe allergies, now available in U.S. with broad access and affordability.
Kartik Rajendran appointed MD of Abbott India, succeeding Swati Dalal post her resignation, effective June 14, 2025.
IMUNON opens first site for Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer patients at Washington University.
Amneal and Apiject partner to boost U.S. production of sterile injectables using advanced BFS technology at Amneal’s Brookhaven facility.
ReciBioPharm licenses NewBiologix’s Xcell-Eng-HEK293 cell line to boost AAV therapy production with high yield, quality, and scalability.
Seamless Therapeutics appoints biotech leader Alvin Shih to its Board to strengthen strategy and advance gene editing therapies.
Merck Animal Health partners with Kansas to invest \$895M in expanding its De Soto facility, boosting manufacturing and R\&D capabilities for animal health.
AVMAPKI FAKZYNJA CO-PACK gains FDA accelerated approval as the first treatment for KRAS-mutated recurrent LGSOC, marking Chugai’s seventh global approval.
Corvus reports Phase 1 data showing soquelitinib improves eczema symptoms with higher efficacy at 400 mg/day vs. placebo, even in patients with severe baseline disease.
Adial to meet with FDA in July to finalise Phase 3 plans for AD04, a precision treatment for Alcohol Use Disorder in genetically identified heavy drinkers.
Shuttle Pharma’s Ropidoxuridine nears 50% enrollment in Phase 2 glioblastoma trial; shows favorable safety and strong adherence with data expected in 2026